Abstract P6-16-04: Phase 1/2a study of glutathione PEGylated liposomal doxorubicin (2B3-101) in breast cancer patients with brain metastases
Philippe Aftimos(Institut Jules Bordet), Dieta Brandsma(Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital), Carey K. Anders(Duke University), Hans Gelderblom(Leiden University Medical Center), Werner Gladdines(BBB Therapeutics (Netherlands)), Bojana Milojkovic-Kerklaan(The Netherlands Cancer Institute), Véronique Dièras(Institut Curie), Agnes Jager(Erasmus MC Cancer Institute), Pieter J. Gaillard, Mónica Arnedos, Patricia M.M.B. Soetekouw(Radboud University Nijmegen), Sevilay Altıntaş(Antwerp University Hospital), Carlos de Sousa(Babraham Bioscience Technologies (United Kingdom)), Jan H.M. Schellens(Utrecht University), Myra van Linde(Amsterdam UMC Location Vrije Universiteit Amsterdam), Ahmad Awada(Centre Hospitalier Interrégional Edith Cavell)
Cited by 6
Related Papers
Palbociclib and Letrozole in Advanced Breast Cancer
|New England Journal of Medicine|2016|2.9k
Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial
|The Lancet|2012|2.1k
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
|Annals of Oncology|2016|2.1k
AACR Project GENIE: Powering Precision Medicine through an International Consortium
|Cancer Discovery|2017|2k
Cremophor EL
|European Journal of Cancer|2001|1.6k